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Abstract
DNA methylation of retroviral promoters and enhancers localized in the provirus 59 long terminal repeat (LTR) is considered to
be a mechanism of transcriptional suppression that allows retroviruses to evade host immune responses and antiretroviral
drugs. However, the role of DNA methylation in the control of HIV-1 latency has never been unambiguously demonstrated, in
contrast to the apparent importance of transcriptional interference and chromatin structure, and has never been studied in
HIV-1-infected patients. Here, we show in an in vitro model of reactivable latency and in a latent reservoir of HIV-1-infected
patients that CpG methylation of the HIV-1 59 LTR is an additional epigenetic restriction mechanism, which controls resistance
of latent HIV-1 to reactivation signals and thus determines the stability of the HIV-1 latency. CpG methylation acts as a late
event during establishment of HIV-1 latency and is not required for the initial provirus silencing. Indeed, the latent reservoir of
some aviremic patients contained high proportions of the non-methylated 59 LTR. The latency controlled solely by
transcriptional interference and by chromatin-dependent mechanisms in the absence of significant promoter DNA
methylation tends to be leaky and easily reactivable. In the latent reservoir of HIV-1-infected individuals without detectable
plasma viremia, we found HIV-1 promoters and enhancers to be hypermethylated and resistant to reactivation, as opposed to
the hypomethylated 59 LTR in viremic patients. However, even dense methylation of the HIV-1 59LTR did not confer complete
resistance to reactivation of latent HIV-1 with some histone deacetylase inhibitors, protein kinase C agonists, TNF-a, and their
combinations with 5-aza-2deoxycytidine: the densely methylated HIV-1 promoter was most efficiently reactivated in virtual
absence of T cell activation by suberoylanilide hydroxamic acid. Tight but incomplete control of HIV-1 latency by CpG
methylation might have important implications for strategies aimed at eradicating HIV-1 infection.
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Introduction
The current protocols of highly active antiretroviral therapy
(HAART) are efficient in decreasing the HIV-1 load below the
limit of detection, reducing mortality due to HIV-1 infection.
Despite the potency of HAART, however, HIV-1 establishes
latent infection in a reservoir of resting memory CD4
+ T cells,
which escapes host immune responses and antiretroviral therapy.
HIV-1 latency is thus the main obstacle to the eradication of the
virus from infected patients [1–5].
Transcriptional shutdown and multistep formation of restrictive
chromatin at long terminal repeats (LTR) are two interconnected
events leading to the latent state of HIV-1 provirus. HIV-1 LTR-
driven transcription is silenced in the absence of cellular
transcription initiation factors NF-kB and NFAT [6,7] or in the
presence of repressors such as CBF-1 and YY1 [8,9]. Low levels of
the Tat transactivator [10] or the Tat-activated elongation factor
P-TEFb [11], and sustained production of prematurely terminated
RNA transcripts from the HIV-1 promoter [12,13] are hallmarks
of HIV-1 latency. At the level of chromatin, entry of HIV-1 into
latency requires recruitment of the histone deacetylase type 1
(HDAC-1) [8,9,14], histone methyltransferase Suv39H1, and
heterochromatin protein HP1 [15,16] to the chromatin around
the HIV-1 LTR. It was suggested that in contrast to the handful of
factors triggering HIV-1 latency, NF-kB alone has the potential to
reactivate HIV-1 from its latent state, and it might be a master
factor in this process [7]. However, more recent reports show that
HIV-1 can be activated in an NF-kB-independent way by
transcription factor DVII-Ets-1, without causing significant T cell
activation [17], and that Lck and NFAT, but not NF-kB, are
PLoS Pathogens | www.plospathogens.org 1 August 2009 | Volume 5 | Issue 8 | e1000554required for optimal latent virus reactivation in primary memory
T cells [18]. Transcriptional reactivation is accompanied by
changes in the local chromatin structure and by the recruitment of
chromatin remodeling factors such as SWI/SNF [19,20] and
histone acetyl transferases such as CBP and p300 [21,22].
CpG methylation of retroviral promoter sequences is another
transcriptional silencing mechanism which contributes to a
difficulty of access of transcription factors to the target DNA.
Not surprisingly, CpG methylation of retroviral promoter and
enhancer sequences situated in the 59 LTR has been correlated
with silencing of various retroviruses, both infectious and
endogenous, as shown for human T-cell leukemia virus type-1
[23,24], Moloney murine leukemia virus [25,26], Rous sarcoma
virus [27,28], and human endogenous retroviruses of the H, K,
and W families [29,30]. The role of proviral DNA methylation in
HIV-1 latency is not clear. CpG methylation of the HIV-1
promoter inhibits transcription of in vitro-methylated plasmids
transfected into cells [31,32], and it has been suggested as a
mechanism for the maintenance of HIV-1 latency in long-term-
infected U937 cells [33] and in latently infected ACH-2 cell line
[34], both cell systems containing silencing mutations in the HIV-1
promoter. In contrast to the previously described systems, we and
others have shown that transcriptional suppression of wild-type
HIV-1 promoter is not accompanied by CpG methylation of the
59 LTR [35–37].
Here, we analyzed the relation of CpG methylation of the HIV-
15 9 LTR to transcriptional suppression and reactivation of HIV-1
provirus in a model consisting of Jurkat clonal cell lines harboring
a latent HIV-1 LTR–driven retroviral vector [38,39]. We
compared our findings obtained in this model with the
relationships between the methylation pattern, latency, and
reactivation of latent HIV-1 provirus in CD4
+ T cells of long-
term aviremic and viremic patients.
Results
Hypomethylation of the HIV-1 59 LTR in Latently Infected
Clonal Cells of Jurkat Lines
To study the role of CpG methylation of the HIV-1 promoter in
proviral latency and during reactivation, we have chosen the
Jurkat clonal cell lines A2, A8, G10, and H12 latently infected with
a ‘‘mini-virus’’ which contained the LTR-Tat-IRES-EGFP-LTR
genome [38], and the cell line JNLGFP latently infected with the
complete EGFP-coding virus [40] (Figure 1). There is a single
proviral copy per cell in lines A2, A8, G10, and H12 and five
copies per cell in line JNLGFP (Table S1). The levels of CpG
methylation in the assayed cell lines were determined by bisulfite
sequencing. In the first step of this technique, sodium bisulfite
converts cytosine residues in the genomic DNA to uracil, but
Author Summary
Despite the potency of highly active antiretroviral therapy
(HAART) to decrease the HIV-1 load and to reduce mortality
due to HIV-1 infection, HIV-1 establishes latent infection
resistant to host immune responses and antiretroviral
therapy. HIV-1 latency is thus the main obstacle to the
eradication of the virus from infected patients. CpG
methylation is a mechanism which contributes to transcrip-
tionalsilencing. The role of proviral DNA methylation in HIV-1
latency has not been clearly demonstrated and has never
been studied in HIV-1-infected patients. We found in an in
vitro model and in HIV-1-infected patients that CpG
methylation of the HIV-1 promoter is important for the
maintenance but not for the establishment of HIV-1 latency.
We show that tight control of HIV-1 latency by CpG
methylation could be a key barrier to purging the reservoir
of latently infected cells in infected individuals. Although our
study shows the difficulty in reactivation of HIV-1 with the
heavily methylated promoter/enhancer sequences from
latently infected cells, it also indicates that addition of some
histone deacetylaseinhibitors (namely suberoylanilide hydro-
xamic acid, SAHA) and cytosine methylation inhibitors would
representanimportantpartofHAARTprotocolsinthefuture.
Figure 1. Methylation profiles of latent promoters of HIV-1
LTR-driven vectors integrated in Jurkat cells. (A) CpG methyl-
ation levels of the 59 LTR of latent HIV-1 LTR-driven retroviral vector
pEV731 coding the HIV-1 protein Tat and EGFP in Jurkat clonal cell
lines A2, A8, G10, and H12, and of the latent complete EGFP-coding
HIV-1 in the JNLGFP cell line. Methylation levels are presented as a
mean6standard error of percentages of methylated CpGs in cloned
HIV-1 promoters for each cell line. Only DNA sequences with at least
95% conversion of cytosines outside CpGs were taken into account.
Levels of EGFP expression (mean6standard error) in all five cell lines
are shown bellow. Significance of the difference in methylation levels
between cell lines was calculated by non-parametric, two-side Mann-
Whitney test. (B) Methylation pattern of the 59 LTR in the H12 cell line.
Analysis of ten promoter molecules is shown as a linear array of open
circles representing nonmethylated CpG residues and closed circles
representing methylated CpG residues. Shown in the rectangle
representing the LTR regions U3, R, and U5 of the pEV731 vector is
the distribution of CpG dinucleotides. (C) Integration site of the latent
HIV-1 ‘‘mini-virus’’ in the H12 cell line. Gray rectangles represent the
exons of ubiquilin. See Table S2 for the flanking sequences. mCpG,
methylated CpG residues.
doi:10.1371/journal.ppat.1000554.g001
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DNA is then amplified by primers specific for the 59 LTR, and the
PCR product is cloned and sequenced. Results are interpreted
based on the assumption that each cloned sequence represents an
individual HIV-1 promoter, and that cytosine residues in the final
sequence represent the 59-methyl cytosines in the template DNA.
Using bisulfite sequencing, we found zero or low levels of CpG
methylation in the 59 LTR (0% in A2, 0% in A8, 2767%
[mean6SEM] in G10, 762% in H12, and 0% in JNLGFP)
(Figure 1A and B). We also found low levels of EGFP expression in
all five cell lines (261% [mean6SEM] of EGFP-positive cells in
A2, 0.460.1% in A8, 0.360.2% in G10, 561% in H12, and
261% in JNLGFP). Thus we confirmed, by means of additional
clonal cell lines, that 59 LTR methylation is not required for HIV-
1 promoter silencing [35]. For the next series of experiments, we
chose the intermediate H12 clonal cell line, harboring a single
proviral copy integrated in the first intron of the ubiquilin gene (chr.
9; 9q21.32) in the sense of the ubiquilin transcription (Figure 1C,
Table S2). Differences between distribution of the 59-methylcyt-
osines in the HIV-1 promoters in the H12 clonal cell line and
other clonal cell lines were not statistically significant.
Cloning of Cells Harboring Latent HIV-1 Provirus
Resistant to Reactivation
To select cells harboring latent HIV-1 provirus resistant to
reactivation, we sorted the H12 cells that after two consecutive
cycles of stimulation with TNF-a and PMA did not express the
HIV-1 reporter gene EGFP (Figure 2A and Figure S1). This
enrichment procedure resulted in increased levels of cells
harboring HIV-1 provirus resistant to reactivation (from 22.2%
after the first negative sorting to 66.2% after the second negative
sorting), while concomitantly, CpG methylation in the 59 LTR
augmented from 7% in H12 cells before the first stimulation to
59% in H12 cells after the second negative sorting (Figure 2A and
Figure S1G). To study the relation between the density of CpG
methylation and the reactivation of latent HIV-1 at the level of
single proviral copy, we cloned the enriched population using
limiting dilution. Reactivation levels of HIV-1 provirus in the
resulting 16 clones stimulated with TNF-a and PMA varied
between 0.4% and 44.5% of cells (Figure 2B), providing a basis for
testing the role of CpG methylation in the process.
Tight Control of HIV-1 Latency is Related to
Hypermethylation of the 59 LTR
For further experiments, we selected the clones 1B6 and 2D12,
which responded distinctly to reactivation with TNF-a and PMA
(Figure 2B) and which showed low spontaneous activity of the
HIV-1 promoter (Figure 2C and F). In the 1B6 clone, stimulation
with TNF-a and PMA reactivated the HIV-1 provirus from
latency in 44.5% of cells (Figure 2D), and 32% of CpGs in the 59
LTR were methylated (Figure 2E). In contrast, the cell clone 2D12
displayed active HIV-1 promoter in only 4.7% of cells after
stimulation with TNF-a and PMA (Figure 2G), and 86% of CpGs
in the 59 LTR were methylated (Figure 2H). Expression of early
activation marker of CD4
+ T cells CD69 on the surface of the
majority of 1B6 cells (97.6%, Figure 2D) and 2D12 cells (86.9%,
Figure 2G) stimulated with TNF-a and PMA shows that the weak
reactivation of HIV-1 promoter was not caused by the inability of
the host cells to be activated. Proportions of methylated CpGs in
both clones stimulated with TNF-a and PMA remained stable for
at least the next 24 h (Figure 2E and H). As shown in Figure 2I,
the density of 59 LTR CpG methylation in clonal cell lines H12,
1B6, 2D12, A2, A8, G10, and in cell cultures derived from the cell
line H12 negatively correlates with the reactivation of HIV-1
promoters, as determined at the transcriptional level by quanti-
tative RT-PCR (not shown) and at the translational level from
expression of EGFP.
Next, we investigated directly whether reactivation of latent
HIV-1 provirus is accompanied by demethylation of the 59 LTR.
For this purpose, we stimulated H12 and 2D12 cells with TNF-a
and PMA for 24 h and performed methylation analysis in sorted
EGFP
+ and EGFP
2 cells (Figure 3). The proportion of methylated
CpG in sorted EGFP
+ H12 cells and EGFP
+ 2D12 cells was not
significantly changed in comparison to non-sorted H12 and 2D12
cells. The proportion of methylated CpG significantly increased in
negatively sorted EGFP
2 H12 cells (as already shown in
Figure 2A). It did not change, however, in sorted EGFP
2 2D12
cells, where the HIV-1 promoter is already heavily methylated.
Taken together, these results show that reactivation of HIV-1
promoter does not require immediate demethylation.
To show that the differences between H12 and 2D12 cells were
not caused by the different capacity to methylate their DNA, we
quantified the global CpG methylation level in genomic DNA of
H12 and 2D12 cells. The differences between these clones were
not statistically significant (7162% of methylated CpG in H12
cells and 6866% of methylated CpG in 2D12 cells).
Differential Susceptibility of Latent HIV-1 with
Hypomethylated and Hypermethylated Promoters to
Reactivation Signals
To assess the resistance of latent HIV-1 with densely methylated
promoter to reactivation we exposed both H12 and 2D12 clones
to TNF-a, to protein kinase C (PKC) agonists (PMA and
prostratin), to inhibitors of HDAC (sodium butyrate (NaBut),
trichostatin A (TSA), suberoylanilide hydroxamic acid (SAHA),
and apicidin), to inhibitors of DNA methyltransferases, DNMT (5-
aza-2-deoxycytidine (5-aza-dC) and zebularine), and/or to their
combinations (Figure 4). Whereas cell activation levels as
measured by expression of the CD69 marker were similar in both
cell lines, reactivation of latent HIV-1 promoter was much
stronger in the H12 cell line than in the 2D12 cell line.
Reactivation of the HIV-1 LTR was determined after 24-h
exposure to reactivation signals. In addition, reactivation with
DNMT inhibitors, weak stimulators of the HIV-1 LTR, was
determined also after 48-h treatment. To measure reactivation of
the HIV-1 LTR on comparable basis, all data were obtained by
gating for live cells after vital staining. Among the examined
inducers, HDAC inhibitors, including TSA, NaBut, SAHA, and
their combinations with other HIV-1-reactivating compounds
showed the highest cell toxicity (Figure S2).
The most important relative differences in reactivation of HIV-
1 promoter in H12 and 2D12 cells were detected for the agonists
of PKC. PMA induced 54% and prostratin 66% of EGFP
+ H12
cells but failed to activate heavily methylated LTRs in 2D12 cells
(as few as 1% and 2% of EGFP
+ 2D12 cells, respectively). The
most efficient inducers of reactivation of the densely methylated
HIV-1 promoter in 2D12 cells were inhibitors of HDAC,
including TSA, NaBut and SAHA. Importantly, the HDAC
inhibitors did not induce significantly higher expression of CD69
than that found in non-induced control cells. Inhibitors of DNMT
did not increase the percentages of EGFP
+ H12 cells over the
background value (13% in both zebularine- and 5-aza-dC-treated
cultures vs. 12% in non-induced H12 cells), and did not induce
significant levels of EGFP in 2D12 cells (0.02% with zebularine
and 0.04% with 5-aza-dC). The most efficient combinations of
inducers in 2D12 cells were combinations of TNF-a or prostratin
with inhibitors of HDAC (TSA, NaBut, and SAHA), and
Epigenetic Control of HIV-1 Latency
PLoS Pathogens | www.plospathogens.org 3 August 2009 | Volume 5 | Issue 8 | e1000554Figure 2. Negative correlation of CpG density in the 59 LTR and reactivation of HIV-1 provirus. (A) Flow chart protocol showing two
consecutive cycles of 24-h stimulation of H12 cells with TNF-a and PMA, followed by the first and second cell sorting of EGFP-negative cells. Negative
sortings are separated by 24-day and followed by 60-day cultivation periods in the absence of any exogeneous stimulator to reach steady-state
culture conditions. In the frames are shown the percentages of EGFP-negative cells determined at the moment of cell sorting and the percentages of
methylated CpGs in HIV-1 promoter determined in the EGFP-negative cell population just after cell separation. (B) Reactivation levels of HIV-1
promoters in clones harboring latent HIV-1. The percentages of EGFP
+ cells in cell clones exposed to TNF-a (10 ng/ml) and PMA (10 nM) for 24 h are
shown. The cell clones were prepared by sublimit dilution of the population of H12 cells 60 days after the second sorting of EGFP-negative cells (as
shown in flow chart protocol, panel A, and in Figure S1, panel I) and analyzed after the outgrowth of cell clones 20 days later. The cell culture from
which the clones were derived was analyzed under the same conditions, 20 days after cell cloning (H12, 26EGFP
2). (C,D) Immunofluorescence of
EGFP and CD69 in 1B6 clone stimulated with TNF-a (10 ng/ml) and PMA (10 nM) for 24 h (D) and in non-stimulated control (C). (E) CpG methylation
profile of the 59 LTR in non-stimulated 1B6 clone and in 1B6 clone stimulated for 24 h. (F,G) Immunofluorescence of EGFP and CD69 in 2D12 clone
stimulated with TNF-a (10 ng/ml) and PMA (10 nM) for 24 h (G) and in non-stimulated control (F). (H) CpG methylation profile of the 59 LTR in non-
stimulated 2D12 clone and in 2D12 clone stimulated for 24 h. (I) Negative correlation of CpG density in the 59 LTR of HIV-1 provirus with EGFP
expression in latently infected Jurkat clonal cell lines exposed to TNF-a and PMA. Open circles, nonmethylated CpG residues; closed circles,
methylated CpG residues (mCpG).
doi:10.1371/journal.ppat.1000554.g002
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synergistic effects (synergistic index .4) were observed between
PMA and apicidin, 5-aza-dC, or zebularine and between 5-aza-dC
and prostratin or apicidin. Although reactivation of HIV-1 from
latency in the 2D12 cell line in comparison with the H12 cell line
was strongly reduced, most tested compounds induced low but
significant expression of the HIV-1 promoter in 2D12 cells.
Hypermethylated HIV-1 59 LTR Is Associated with
Repressive Chromatin Structure
To elucidate the contribution of chromatin structure to the
maintenance of the latent state of HIV-1, we investigated histone
modifications at hypo- and hypermethylated HIV-1 59 LTRs
(Figure 5). We found that the levels of histone 3 (H3) dimethylated
on lysine 4 (diMeH3K4), representing active chromatin, that were
associated with HIV-1 promoter were significantly lower in 2D12
cells than in H12 cells (89.8 times lower in non-stimulated cells and
65.7 times lower in stimulated cells). In contrast, the levels of
acetylated H3, another marker of active chromatin, in non-
stimulated cells of both cell lines were similar. After stimulation,
the levels of acetylated H3 increased (6.2 times in H12 cells and
2.3 times in 2D12 cells). The levels of H3 trimethylation on lysine
9 (triMeH3K9), representing repressive chromatin, in non-
activated cells were 4.1 times higher in cells of the 2D12 line
than in cells of the H12 line. The levels of triMeH3K27, also
representing repressive chromatin, dropped 13.1 times after
activation of H12 cells. In non-activated cells, the triMeH3K27
levels were 2.9 times higher in 2D12 cells than in H12 cells.
Whereas after activation the level of H3K9 trimethylation in cells
of the H12 line did not significantly change, it decreased 2.9 times
in cells of the 2D12 line. Thus, hypermethylated DNA of proviral
promoter in 2D12 cells is more strongly associated with repressive
chromatin structure than hypomethylated DNA of proviral
promoter in H12 cells.
Hypermethylation of the HIV-1 59 LTR in Long-Term
Plasma Viremia Negative HIV-1-Infected Individuals
Our next aim was to compare the methylation pattern of latent
HIV-1 promoter in our in vitro model with that in infected
individuals. We inspected the 59 LTR CpG methylation in latent
reservoirs of resting CD4
+ T cells in patients in whom HAART
resulted in long-term suppression of plasma viremia and in viremic
patients (Table 1 and Table S3). The low percentage of HIV
provirus-harboring cells in the latent reservoir and the low
sensitivity of PCR after bisulfite treatment of DNA hampered
determination of the methylation pattern in several analyzed
patients. Thus, from a cohort of 18 HAART-treated patients
without detectable plasma viremia, we analyzed six individuals,
and from 13 viremic patients we analyzed seven individuals with
$10
3 HIV-1 DNA copies per million CD4
+ cells (Table 1 and
Figure 6A and B).
The 59 LTR of HIV-1 in six patients without detectable plasma
viremia contained 20%, 30%, 48%, 71%, 96%, and 100% of
methylated CpGs compared with ,0.1% of methylated CpGs in
HIV-1 promoters in a control group of viremic patients
(p=0.0012, Figure 6B). This striking difference shows that the
high level of CpG methylation is a specific characteristic of HIV-1
promoters in aviremic patients. However, numerous non-methyl-
ated proviral sequences were found, particularly in two patients
with the lowest level of methylated CpGs (patients 14 and 18). We
further analyzed the sequence variability of HIV-1 promoters of
aviremic patients in the set of sequences obtained after bisulfite
treatment. Although rigorous phylogenetic analysis of the bisulfite-
treated 59 LTR of HIV-1 sequences is precluded by the conversion
of the majority of cytosine residues to thymine (except for
methylated cytosine residues), we used the neighbor-joining
method to compare different sequences of HIV-1 promoters. In
three aviremic patients harboring the lowest proportion of
methylated CpGs in the 59 LTR of HIV-1 (patients 13, 14, 18),
the non-methylated and methylated sequences clearly segregate in
different sequence clusters (Figure 6A). Also densely methylated
sequences (patients 4 and 9) clustered in two different groups. In
conclusion, limited numbers of HIV-1 proviruses with hyper-
methylated promoters are present in the long-term HAART-
treated aviremic individuals in contrast to non-methylated
promoters of viremic patients.
Truncated HIV-1 Sequences Do Not Prevail in Memory
CD4
+ T Cells of Aviremic Patients
Clusters of identical or nearly-identical 59LTR sequences point
to a usually observed variability of HIV-1 sequences in infected
persons and arise the question whether the HIV-1 sequences
analyzed for the methylation profile represent replication-compe-
tent or defective proviruses. To this end, we assayed whether a
significant subset of defective proviruses consisting of extremely
deleted HIV-1 genomes [41] is more prevalent in memory CD4
+
T cells of viremic or aviremic patients. This subset of defective
proviruses, detected in PBMCs of most HIV-1-infected persons,
can be formed by reverse transcriptase jumps over the central part
of HIV-1 genomes, so that the resulting molecules more frequently
contain the LTRs than the central sequences of HIV-1 genome
[41]. Quantitative PCR was used to compare the quantity of the
central (tat gene) and terminal (LTR) HIV-1 sequences, and to
determine the LTR/tat ratio (Protocol S1 and Table 1). Therefore,
by means of the LTR/tat ratio we estimated the proportion of
truncated to full-length proviruses in viremic and aviremic
patients. We have not found any significant differences between
the levels of tat and LTR sequences in DNA of aviremic patients 4,
10, 14, and 18. In DNA of all tested viremic patients, we have
found prevailing terminal LTRs over tat sequences, consistently
with our previous demonstration that accumulation of truncated
proviruses is a consequence of HIV-1 replication in infected
Figure 3. DNA methylation levels of the 59 LTR after
reactivation of HIV-1 promoter from latency. H12 and 2D12 cells
activated with TNF-a and PMA for 24 h (86% EGFP
+ H12 cells and 28%
of EGFP
+ 2D12 cells) were separated by FACS according to the
expression of EGFP and analyzed for CpG methylation. Percentages of
methylated CpGs are presented as a mean6SEM.
doi:10.1371/journal.ppat.1000554.g003
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PLoS Pathogens | www.plospathogens.org 5 August 2009 | Volume 5 | Issue 8 | e1000554Figure 4. Reactivation of HIV-1 latency in clones harboring proviruses with densely (2D12) and weakly (H12) methylated 59 LTR.
Percentages of EGFP
+, CD69
+, and EGFP
+/CD69
+ cells in the population of H12 and 2D12 clonal cell lines stimulated with the indicated substances were
determined by means of flow cytometry. All data were obtained by gating for live cells after vital staining with Hoechst 33258. Results that represent
duplicates or several independent experiments are presented as means6SD. Additive (A) and synergistic (S) effects between two inducers of HIV-1
reactivation are assigned for 2D12 cell line. The index of synergism (in brackets) was determined from the following formula: the percentage of EGFP
+
cells after stimulation with the combination of stimulators divided by the sum of percentages of EGFP
+ cells after stimulation with the stimulators
separately. As synergistic were considered the combinations resulting in the index of synergism .1.5. As additive were considered the combinations
resulting in the index of synergism #1.5 and in .30% increase of stimulation in comparison to stimulation with one out of two stimulators.
doi:10.1371/journal.ppat.1000554.g004
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in the majority of aviremic patients.
Tight Control of HIV-1 Latency ex vivo Is Related to
Hypermethylation of the HIV-1 59 LTR of HIV-1-Infected
Individuals
Finally, we investigated whether the density of CpG methylation
of HIV-1 promoters harbored in memory CD4
+ T cells of long-
term aviremic individuals correlates with the resistance of HIV-1
to reactivation signals. To this end, purified memory CD4
+ T cells
of HIV-1-infected individuals were stimulated with TNF-a and
PMA, with TSA and PMA, and with 5-aza-dC for three days; they
were serially diluted and co-cultured with allogeneic phytohemag-
glutinin (PHA)-activated CD4
+ T cells; and the quantity of HIV-1
secreted to cell-free supernatant was determined (Figure 6C–F).
The results show a negative correlation between methylation levels
of the HIV-1 59 LTR and percentage of reactivable proviruses ex
vivo calculated on the basis of end point titers from aviremic
Figure 5. Chromatin structures associated with active and latent states of HIV-1 promoter. Histone 3 (H3) modifications of HIV-1
promoter in the H12 and 2D12 cell lines were analyzed by means of the quantitative ChIP assay using the indicated antibodies before (NI) and after
stimulation with TNF-a (10 ng/ml) and PMA (10 nM) (H3CT, anti-H3 C-terminus antibody; diMeH3K4, anti-H3 dimethylated on lysine 4 antibody;
AcH3, anti-acetyl-H3 antibody; triMeH3K9, anti-H3 trimethylated on lysine 9 antibody, triMeH3K27, anti-H3 trimethylated on lysine 27 antibody). The
equal quantities of HIV promoter immunoprecipitated with anti-H3 C-terminal domain antibody in both cell lines before and after stimulation shows
that the total quantity of H3 remained constant. As a control, the cell extracts were immunoprecipitated with normal rabbit IgG. The amount of
immunoprecipitated material was normalized to the input DNA. Note that quantities of immunoprecipitated DNA cannot be compared between
different H3 modifications, as quantitation is not absolute and depends on antibody affinity. The experiments were performed in triplicates.
doi:10.1371/journal.ppat.1000554.g005
Table 1. CpG methylation of HIV-1 promoter and quantitation of truncated HIV-1 in patients without detectable plasma viremia
and in viremic controls.
No. Age Sex Therapy
a
On therapy
from CD4/mm
3
Plasma charge
(copies/ml)
DNA proviral
copies/10
6 cells
b LTR/tat
c CpG methylation (%)
Aviremic 4 41 M 2 NRTI+NNRTI 1992 586 ,50 2610
3 0.5 (ns) 100
9 43 M 2 NRTI+PI 1996 417 ,50 4610
3 200 (p=0.002) 74
10 37 M 2 NRTI+NNRTI 1997 958 ,50 1610
3 1.5 (ns) 96
13 47 F 2 NRTI+PI 1995 175 ,50 1610
5 ND 61
14 35 F 2 NRTI+PI 2000 650 ,50 8610
3 0.97 (ns) 19
18 54 M 2 NRTI+PI 2005 540 ,50 2610
3 3.7 (ns) 30
Viremic v4 36 M TN - 556 108,843 4610
3 ND 0
v7 67 M TN - 638 101,107 1610
3 ND 0
v9 42 M 2 NRTI+PI 1997 580 69,177 1610
4 ND 0
v10 49 M 2 NRTI+PI 1989 144 420 2610
3 14 (p=0.01) 0
v11 57 M NRTI+NNRTI+PI 1995 661 2,721 5610
3 2190 (p=0.001) 0
v12 50 M 2 NRTI+PI 2008 400 600 1.7610
4 13 (p=0.02) 0
v13 47 F 2 NRTI+PI 1995 200 1,432 1.5610
4 ND 0.1
aNRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; TN, treatmentn a ı ¨ve. See Table S3 for more
details.
bDetermined by quantitative PCR as described in Protocol S1.
cProportion of truncated to full-length proviruses. The titers of LTR and tat sequences were determined by quantitative PCR as described in Protocol S1. ns, non-
significative difference, p, non-parametric, two side Mann-Whitney test; ND, not-determined.
doi:10.1371/journal.ppat.1000554.t001
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and PMA (Figure 6D and E). These HIV-1 inducers reactivated
proviruses only from the memory CD4
+ T cells of long-term
aviremic individuals harboring high proportions of non-methylat-
ed promoters (patients 14 and 18). Neither the combination of
TNF-a and PMA nor that of TSA and PMA reactivated HIV-1
proviruses with promoters containing $48% of methylated CpGs
(n=4). Although memory CD4
+ T cells were stimulated in the
presence of IL-2 and in the absence of inhibitors of integrase, no
outgrowth of possibly non-integrated proviruses was observed in
Figure 6. Methylation analysis of HIV-1 promoter in memory CD4
+ T cells purified from HIV-1-infected individuals. Hypermethylation
of the HIV-1 59 LTR in HIV-1-infected long-term aviremic individuals contrasts with hypomethylation of the HIV-1 59 LTR in viremic patients and
negatively correlates with reactivation of the HIV-1 provirus. (A) CpG methylation patterns in the bisulfite-treated HIV-1 59 LTR sequences of aviremic
patients were clustered using neighbor-joining method into several groups within each patient (separated by horizontal bars) with a strong
bootstrap support (.990/1000). The sequences within each group differed in addition in about 1 to 10 point-mutations. Note that the variability of
bisulfite-treated sequences is underestimated due to the conversion of the majority of cytosine residues to thymine (except for cytosine in 5-
methylcytosine residues). Open circles, nonmethylated CpG residues; closed circles, methylated CpG residues. (B) Percentage of methylated CpGs
(mCpG) in the 59 LTR of HIV-1 in long-term aviremic (n=6) and viremic (n=7) patients. p, non-parametric, two side Mann-Whitney test. (C–F)
Reactivation of HIV-1 provirus in memory CD4
+ T cells obtained from patients with different levels of CpG methylation. Memory CD4
+ T cells cultured
for three days in the presence of reactivating agents were 10-fold serially diluted in duplicate and co-cultured with PHA-activated CD4
+ T cells from
an allogeneic healthy donor. HIV-1 replication was followed by determination of p24 in the cell-free supernatant. Percentage of reactivable provirus is
presented as a ratio of end-point dilutions of patients’ CD4
+ T cells producing HIV-1 virus to the number of DNA proviral copies in the cell quantity
equivalent to end-point dilution and determined by quantitative PCR, as indicated in Table 1. (C) Non-stimulated CD4
+ T cells. (D) CD4
+ T cells
stimulated with TNF-a at 10 ng/ml and 10-nM PMA. (E) CD4
+ T cells stimulated with 500-nM TSA and 10-nM PMA. (F) CD4
+ T cells stimulated with 5-
mM 5-aza-dC. (C–F) Open symbols, viremic patients; closed symbols, aviremic patients.
doi:10.1371/journal.ppat.1000554.g006
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provirus containing 96% of methylated CpGs (n=1) with 5 mM5 -
aza-dC shows that memory CD4
+ T cells of this patient contained
replication-competent virus, which could be reactivated by the
demethylating agent (Figure 6F). In contrast to proviruses in
aviremic individuals, which are hardly reactivable ex vivo, CD4
+ T
cells of all viremic patients produced HIV-1 as a result of three-day
culture in the presence of IL-2 followed by a simple co-culture with
allogeneic PHA-activated CD4
+ T cells (Figure 6C).
Discussion
Our present work demonstrates that CpG methylation of the
HIV-1 59LTR could be an important epigenetic mechanism that
maintains the latency of HIV-1 proviruses by preventing their
reactivation. Our results explain the ambiguous conclusions
emerging from methylation studies in cell lines latently infected
with HIV-1 [31–36,43] and, of particular importance, correlate
the in vitro data with data from HIV-1-infected patients. CpG
methylation in HIV-1-infected patients has not been studied so far.
In spite of the low number of HIV provirus-harboring cells in the
latent reservoir and the decreased sensitivity of PCR after bisulfite
treatment of DNA, our work shows the possibility of studying, and
possibly acting upon, the epigenetic control of HIV-1 latency in
infected individuals.
Tight control of HIV-1 latency by CpG methylation of the 59
LTR could be important for the maintenance of, and ultimately
for purging, the reservoir of latently infected cells in infected
individuals. The high resistance of densely methylated latent HIV-
1 proviruses in the 2D12 cell line and in CD4
+ T cells of aviremic
patients to the majority of HIV-1-reactivating compounds tested in
our work illustrates the difficulty of purging the reservoir of latent
HIV-1 with T-cell-activating agents such as IL-2 and OKT3
[1,2,44], prostratin [45–47], and IL-7 [47–49]. On the other hand,
the resistance of densely methylated HIV-1 proviruses to
reactivation signals was incomplete, and we can assume that even
these proviruses are not stably latent and could produce infectious
progeny after suitable stimulation. Thus, a high methylation level
of the 59 LTR contributes to the multiple mechanisms controlling
HIV-1 latency that make eradication of HIV-1 problematic, unless
new approaches are developed.
In addition to epigenetic mechanisms, the expression of HIV-1
proviruscanbe abrogatedby genetic defects. The59LTRsequences
from infected viremic or aviremic patients analyzed by bisulfite
sequencing did not show any significant mutations in comparison
with corresponding sequences present in the HIV-database [50]. It
is, however, difficult to screen genetic defects in the inner HIV-1
sequences; long-distance sequence analysis of DNA adjacent to
LTR is hampered on the bisulfite-treated template and our analysis
of defective viruses detects just gross deletions containing the tat
region. Using the 5-aza-dC, we have rescued the replication-
competent virus from one patient (No. 10) where 59LTR sequences
display almost full methylation of all CpGs. Although we cannot
completely exclude the possibility of virus rescue from a non-
methylated provirus that escaped our methylation analysis, this
result strongly suggests that the parental replication-competent
HIV-1 proviruses in this patient contain nearly fully methylated
promoters. At the moment, we are unable to quantify the
proportion of the latent replication-competent proviruses in the
whole proviral population. As the first approximation we used a
quantitative assay, by means of which we detected significantly
higher proportion of defective truncated proviruses in viremic than
in aviremic patients. This testifies against the possibility that
methylated proviruses are preferentially defective.
We extended here our previous in vitro results showing that CpG
methylation of the HIV-1 59 LTR is not necessary for the
establishment of viral latency [35]. Indeed, the latent reservoir of
some aviremic patients contained high proportions of the non-
methylated 59 LTR. However, the latency controlled solely by
transcriptional interference and by chromatin-dependent mecha-
nisms tends to be leaky and easily reactivable. On the basis of our
results, we propose a two-step model of epigenetic control of HIV-
1 latency (Figure 7). The hypomethylated HIV-1 59 LTR in the
state of reactivable latency in the clone H12 is significantly less
associated with acetylated H3 chromatin structure than that in the
active state after provirus reactivation. In contrast, dense CpG
methylation of the proviral promoter (exemplified by the clone
2D12), probably together with hallmarks of the repressive histone
code such as low levels of H3K4 di-methylation and high levels of
H3K9 and H3K27 tri-methylation, could contribute to the
‘‘locked’’ silent state of the provirus and make the return of the
provirus to an active state inefficient [51].
Reactivation of HIV-1 promoter is not accompanied by
significant demethylation of CpG in the 59 HIV-1 LTR
(Figure 3); however, it is accompanied by a rapid drop of H3K9
trimethylation. Indeed, inhibitors of DNMT alone do not induce
reactivation of the HIV-1 promoter in 2D12 cells. In contrast, the
HDAC inhibitors, TSA, NaBut, and namely SAHA, efficiently
reactivate the densely methylated HIV-1 promoter. Moreover,
HDAC inhibitors, which are generally anti-inflammatory [52],
reactivate HIV-1 latency in virtual absence of T cell activation;
this corroborates the results shown previously in the context of
HIV-1 reactivation from latency by transcription factor DVII-Ets-
1 [17]. Activation of CD4
+ T cells is, therefore, dispensable for
reactivation of HIV-1 provirus. Among assayed inducers of
reactivation of HIV-1 promoter, only PKC agonists were
concomitantly strong inducers of the early marker of activation
of T cells, CD69. Thus, chromatin changes precede CpG
methylation of the 59 LTR in the course of establishment of
HIV-1 latency, and chromatin changes also initiate reactivation of
latent HIV-1 in spite of the presence of demethylated CpG
(Figure 7). This kinetics corresponds well with the fact that passive
demethylation occurring in the S-phase of the cell cycle is rather
slow to precede the rapid onset of activation. In contrast to our
results, a clear trend toward demethylation of CpG has been
observed after 48 hours of TNF-a treatment of cell line ACH-2
[34]. CpG demethylation after reactivation of latent HIV-1 by
different signals in different cell lines is intensively studied in our
laboratories.
As in the majority of latently infected cells in infected individuals
[53,54], the HIV-1 provirus in the H12 cell line is integrated
within a gene. Surprisingly, distinct levels of resistance of HIV-1
provirus to reactivation could be established at the same
integration site. Thus, the HIV-1 latency in H12 cells is
reactivation-prone, whereas in 2D12 cells with the provirus
inserted at exactly the same genomic site the HIV-1 latency is
reactivation-resistant. Both distinct states of HIV-1 latency are
quasi-stable during cell divisions and both states are re-established
after the return of reactivated HIV-1 to a basal latent state.
Positive selection of EGFP
+ H12 cells harboring reactivated virus
also results in the return to a basal latent state with an unchanged
methylation profile in the absence of the activation stimulus;
however, tightly controlled HIV-1 proviruses could be negatively
selected from the population of EGFP
2 H12 cells resistant to
HIV-1-reactivating compounds. At the moment, we study
frequency of highly restricted viruses negatively selected from
additional clones harboring HIV-1 proviruses with hypomethy-
lated promoters.
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levels. We suppose that both extremes of methylation density can
be selected in different experimental settings as a function of
reactivation-proneness of latently infected cells. During the
development of models of reactivable latency [37–40], clones
harboring readily reactivable provirus have been selected from the
population of cells following integration of the virus in the absence
of viral gene expression (silent integration) [37]. As exemplified by
the cell line H12, selection of such cell lines results in proliferation
of cell clones with hypomethylated 59 LTR and leaky control of
provirus transcription. In inverse order to the events performed in
previous works [37–40], we negatively selected from the
population of cell line H12 the cells harboring a latent provirus
resistant to reactivation. This procedure resulted in the outgrowth
of cell clones with hypermethylated 59 LTR and tight control of
provirus transcription, exemplified by the cell line 2D12. It is
possible that a similarly tight control of HIV-1 promoter
reactivation by hypermethylation was necessary to select latently
infected cells by silencing of actively replicating virus from
chronically infected cell lines U937 and ACH-2 [55–57]. Indeed,
HIV-1 promoter in these historically first described latent cell lines
is heavily methylated [33,34].
It is difficult to speculate about the exact transcriptional status of
heavily methylated HIV promoters in aviremic patients and their
contribution to residual viremia [58–64]. Their reactivation is
probably a rare and stochastic event as suggested by the sequential
homogeneity of virus rebounding during the short structured
treatment interruptions [58]. While immunologic stimuli in vivo are
adequate to overcome CpG methylation-mediated suppression of
HIV-1 expression in virtually all patients who discontinued
HAART, resistance of highly methylated HIV-1 promoters in
memory CD4
+ T cells purified from aviremic patients to
reactivation ex vivo could be related to low HIV-1 DNA copy
numbers in assayed aliquots. Our ex vivo experiments suggest that
proviruses with densely methylated promoters coexist in some
aviremic patients with latent but easily reactivable proviruses
controlled by non-methylated promoters. In contrast to aviremic
patients, non-methylated promoters present in viremic patients are
expressed in the absence of external stimuli. HIV-1 was rescued
from virtually all provirus-containing cells of viremic patients,
without any evidence of DNA methylation. The non-methylated
status of HIV-1 promoters in viremic patients might be further
enhanced by the presence of unintegrated viral DNA, abundant
during the viremic phase of HIV-1 infection [65]. Thus, the virus
recovered from memory CD4
+ T cells of viremic patients may
represent, in addition to the product of integrated proviral
genomes, also the product of pre-integrated HIV-1 DNA.
We suppose that during the acute phase of HIV-1 infection
accompanied by stimulation of the immune system [66–70],
memory CD4
+ T cells harboring reactivation-resistant latent HIV-
1 that contained hypermethylated promoters have a better chance
to escape from virus-induced cytopathic effects and cytotoxic
responses than those infected with reactivation-prone hypomethy-
lated provirus. Thus, the presence of hypermethylated HIV-1
promoters in CD4
+ T cells of patients with long-term suppressed
viremia could be the result of selection of proviruses with tightly
controlled latency. In contrast, memory CD4
+ T cells harboring
reactivation-prone HIV-1 proviruses with hypomethylated pro-
moters could be counter-selected by a virus-specific cytopathic
effect and cytotoxic responses during perpetual stimulation of
the immune system. Patients’ cells analyzed in our experiments
were sorted for memory, but not activation, CD4
+ T phenotype.
It is probable that the frequency of activated memory cells is lower
in aviremic than in viremic patients and that the difference in
the methylation pattern between both groups is strengthened by
this effect.
Figure 7. Two-step model of epigenetic control of HIV-1 latency. In the state of reactivable latency exemplified by the H12 cell line, the HIV-1
promoter is hypomethylated, histone 3 (H3) is methylated on lysine 4 (MeK4), but deacetylated by histone deacetylases (HDAC), nuc-0 and nuc-1 are
in proximal position; chromatin is condensed. After reactivation with TNF-a and PMA, the hypomethylated HIV-1 promoter-associated H3 is
acetylated by means of histone acetyltransferases (HAT). Nucleosomes nuc-0 and nuc-1 are in distal position. In the ‘‘locked’’ silent state exemplified
by the 2D12 cell line, the HIV-1 promoter is methylated by DNMT, and H3 is demethylated on K4 and methylated on K9 (MeK9) and K27 (MeK27).
After reactivation of the hypermethylated HIV-1 promoter the HIV-1 LTR-associated H3 remains methylated on K27 but is demethylated on K9; CpG
methylation is not changed and the repression is overcome by excess of transcription factors. The percentage of cells harboring reactivated HIV-1 is
markedly lower in the clone with the ‘‘locked’’ highly methylated promoter (2D12) than in the clone with hypomethylated promoter (H12). Open
circles, nonmethylated CpG residues; closed circles, methylated CpG residues, TFs, transcription factors.
doi:10.1371/journal.ppat.1000554.g007
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cause of our inability to purge the reservoir of latent HIV-1 in
infected individuals. Methylation of the HIV-1 59 LTR is an
additional restriction mechanism, which controls resistance of
latent HIV-1 against reactivation signals and thus determines the
stability of the HIV-1 latency, although it is not required for the
initial silencing events and it needs not to be reverted immediately
during reactivation. Reactivation of HIV-1 latency in virtual
absence of T cell activation by SAHA, an HDAC inhibitor already
approved for use in humans, and strong synergistic effects between
59aza-dC and other activators of HIV-1, may represent an
important step toward the elimination of the latent HIV-1
reservoir. CpG methylation accompanied by repressive histone
code seems to be the ultimate step in the development of the
‘‘locked’’ silent state of the provirus. The high stability of the
locked silent state is, however, not complete. High but incomplete
resistance of HIV-1 to reactivation represents a therapeutic
challenge for the future.
Materials and Methods
Ethics Statement
This study was conducted according to the principles expressed
in the Declaration of Helsinki. Each patient provided informed
written consent to participation in this study in accordance with
institutional and regulatory guidelines. The study was approved by
the Institutional Review Board of Ambroise Pare ´ Hospital.
Patients
Seropositive individuals were selected for the study on the basis
of at least two years of lasting infection and non-detectable plasma
viral load during the last year (,50 HIV-1 RNA copies per
milliliter of plasma as determined with Amplicore Ultrasensitive
HIV-1 Monitor Assay; Roche Molecular Diagnostic System).
Viremic individuals with plasma viremia from 6610
4 to 1610
5
RNA copies per milliliter of plasma were analyzed as controls.
Preparation of Memory CD4
+ T Cells from PBMCs of HIV-
1-Infected Patients
Patients’ PBMCs (aliquots of 2610
7 cells) were separated on
Ficoll-Hypaque gradients. Memory CD4
+ T cells separated from
PBMC by means of a memory CD4
+ T cell isolation kit (Miltenyi
Biotech, France) were cultured at the concentration of 10
6 cells per
milliliter of RPMI 1640 supplemented with 200-U/ml recombi-
nant IL-2 (Chiron), 15% fetal calf serum, and antibiotics in
duplicate in a total volume of 100 ml in the presence of HIV-1-
reactivating agents. After a 3-day stimulation, CD4
+ T cells were
10-fold serially diluted and co-cultured with PHA-activated CD4
+
T cells from an allogeneic healthy donor, as described in detail
previously [71]. HIV-1 replication was followed by determination
of p24 in the cell-free supernatant by means of Genetic System
HIV Ag EIA (BioRad France, Marnes la Coquettes). CD4
+ T cells
infected with HIV-1 NL4-3 or with HIV-1 AD8 were used as
positive controls.
Clonal Cell Lines
Cell lines A2, A8, G10, and H12 were prepared by transduction
of Jurkat cells with the HIV-1-based vector (pEV731 vector from
the pHR’ series) containing Tat and EGFP under the control of
the HIV-1 LTR (LTR-Tat-IRES-EGFP-LTR), as described
previously [38]. The JNLGFP Jurkat cell line contains multiple
copies of integrated full-length HIV-1 provirus including the
EGFP open reading frame placed between the env and nef genes
[40]. H12 cells stimulated with TNF-a and PMA were separated
by cell sorting of EGFP negative cells with FACSAria (BD
Biosciences).
Reactivation of Latent HIV-1 Provirus
To reactivate the HIV-1 provirus from latency, we treated the
cell lines or patients’ memory CD4
+ T cells with 10-nM PMA
(Sigma-Aldrich), TNF-a (Sigma-Aldrich) at 10 ng/ml, 1 or 5-mM
5-aza-dC (Sigma-Aldrich), 500-nM TSA (Sigma-Aldrich), 5-mM
prostratin, 5-mM NaBut, 2.5-mM SAHA, 0.5-mM apicidin and
500-mM zebularine, or with their different combinations.
Flow Cytometry Analysis
We analyzed EGFP
+ and anti-CD69-phycoerythrin-labeled
(Becton-Dickinson) viable cells, negative for staining with Hoechst
33258 (Sigma-Aldrich) at 1 mg/ml, with LSR II and FACSCalibur
flow cytometers, using CELLQuest and FlowJo software (Becton-
Dickinson, Le Pont de Claix, France). EGFP+ cells were isolated
using FACSAria cell sorter (Becton Dickinson).
Cloning of H12 Cells
Aliquots, 200 ml each, of H12 cells diluted to the concentration
of one cell per 2 milliliters were distributed into 96-well microtiter
plates as specified in Protocol S1. Subcultures were expanded
further.
Bisulfite Cytosine Methylation Analysis
The samples of total genomic DNA isolated with the QIAamp
DNA Blood Mini Kit (Qiagen Inc.) were digested overnight with
EcoRI and prepared for methylation analysis as described by
Hajkova et al. [72], or proceeded to methylation analysis by means
of the Epitect Bisufite Kit (Qiagen Inc.).
Bisulfite-treated DNA was amplified by means of PCR in a 50-
ml reaction mixture containing 50 mM Tris-HCl (pH 9.2),
1.75 mM MgCl2, each dNTP at 350 mM, and each primer at
45 pmol: MB (59-TGGTAGAATTATATATTAGGGTTAGG-
GATT-39, nucleotides [nt] 81 to 110, sense), MH (59-CACC-
CATCTCTCTCCTTCTAACCTC-39, nt 772 to 796, antisense)
and MC (59-AGAGAAGGTAGAAGAAGTTAATGAAG-
GAGA-39, nt 161 to 190, sense); MG (59-AAAAAACTCCTC-
TAATTTCCCTTT-39, nt 663 to 686, antisense) or MF instead of
MG (59- AAATCTAAAAAATCTCTAATTACCAAAATC-39,
nt 577 to 606, antisense) for the HIV 59 LTR. The sense primers
contained T and the antisense primers A instead of C in positions
complementary to non-methylable C (i.e., C out of CpG
dinucleotides). PCR was performed with about 50 ng of genomic
DNA for 40 cycles at 95uC for 60 s, 58uC for 120 s, and 72uC for
60 s. Amplification products were cloned in the pGEM-T-Easy
Vector System (Promega, Madison, WI) and sequenced. Only
PCR clones with at least 95% conversion of cytosines outside
CpGs were taken into account.
Clustering of Patients’ HIV-1 LTR Sequences
The sequences of different HIV-1 LTRs amplified after bisulfite
treatment of aviremic patients’ DNA samples were clustered
within each patient using the neighbor-joining method. The
bootstrap support was very strong for the distinct clusters. All
CpGs were masked for this analysis to exclude the differences in
the methylation status.
Quantification of Global DNA Methylation
The Methylamp
TM Global DNA Methylation Quantification
Ultra Kit (Epigentek) was used according to the manufacturer’s
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in H12 and 2D12 Jurkat clonal cell lines.
ChIP
ChIP assays were performed by means of the ChIP assay kit
(Upstate Biochemicals, Temecula, CA). H12 and 2D12 Jurkat
clonal cell lines were non-induced or induced with TNF-a (10 ng/
ml) and PMA (10 nM) 20 min before ChIP assays. The analyzed
cells were then cross-linked in the presence of 1% formaldehyde
for 10 min at room temperature. Chromatin was sheared by
sonication for 45 min in total (30 s ON, 30 s OFF) to obtain DNA
fragments of about 200 bp in a Bioruptor (Diagenode SA, Liege,
Belgium). The antibodies used for ChIP were as follows: anti-
histone H3, CT, pan (Millipore-Upstate, Holsheim, France), anti-
acetyl-histone H3 (Millipore-Upstate), anti-dimethyl-histone H3
(Lys4) (Millipore-Upstate), anti-trimethyl-histone H3 (Lys9) (Milli-
pore-Upstate) and anti-trimethyl-histone H3 (Lys 27) (Abcam,
Cambridge, UK). For the control, we immunoprecipitated the cell
extracts using normal rabbit IgG (Millipore-Upstate) instead of
hyperimmune antibody. Immunoprecipitated DNA was subjected
to real-time PCR quantification using primers specific for the 59
LTR (forward: 59-TTAGCAATGTGTATGGGAGTTGA-39,
reverse: 59-ATATCTTGTCTTCGTTGGGAGTG-39).
Supporting Information
Protocol S1 Quantitative PCR and RT-PCR. Quantification of
truncated HIV-1 proviruses. Inverse PCR. Cell cloning.
Found at: doi:10.1371/journal.ppat.1000554.s001 (0.07 MB PDF)
Table S1 Number of proviral copies in latently transduced
Jurkat clonal cell lines.
Found at: doi:10.1371/journal.ppat.1000554.s002 (0.03 MB PDF)
Table S2 Flanking sequences of HIV-1-based vector integrated
in the first intron of the ubiquilin gene in the cell line H12.
Found at: doi:10.1371/journal.ppat.1000554.s003 (0.03 MB PDF)
Table S3 Antiretroviral therapy in patients without detectable
plasma viremia (,50 copies/ml).
Found at: doi:10.1371/journal.ppat.1000554.s004 (0.05 MB PDF)
Figure S1 Selection of H12 cells resistant to reactivation of
HIV-1 provirus from latency. (A) Flow chart protocol showing
activations of H12 cells with TNF-a and PMA, the first and
second cell sorting of EGFP-negative cells, and cultivation periods
in the absence of exogeneous activator. (B) Immunofluorescence of
EGFP in non-activated H12 Jurkat cells. (C) Immunofluorescence
of EGFP in H12 cells exposed to TNF-a (10 ng/ml) and PMA
(10 nM) for 24 h. (D) CpG methylation profile of the 59 LTR in
H12 cells exposed to TNF-a and PMA for 24 h and negatively
sorted for EGFP. (E) Immunofluorescence of EGFP in H12 Jurkat
cells activated with TNF-a and PMA for 24 h, negatively sorted
for EGFP, and then kept in culture in the absence of exogeneous
activator for 24 days. (F) Immunofluorescence of EGFP in H12
Jurkat cells cultured as in (E) and stimulated for the second time
with TNF-a and PMA for 24 h. (G) CpG methylation profile of
the 59 LTR in H12 cells cultured as in (F), negatively sorted for the
second time for EGFP. (H) Immunofluorescence of EGFP in H12
Jurkat cells cultured as in (F), negatively sorted for EGFP, and then
kept in culture in the absence of exogeneous activator for 60 days.
(I) Immunofluorescence of EGFP in H12 Jurkat cells cultured as in
(H) and stimulated for the third time with TNF-a and PMA for
24 h. (J) CpG methylation profile of the 59 LTR in H12 cells
cultured as in (H). Open circles, nonmethylated CpG residues;
closed circles, methylated CpG residues. Bars in B, C, E, F, H, and
I represent percentages of EGFP-positive cells.
Found at: doi:10.1371/journal.ppat.1000554.s005 (0.13 MB PDF)
Figure S2 Survival of H12 and 2D12 cells treated with HIV-1
inducers. Percentages of live H12 and 2D12 cells relative to non-
induced (NI) control were determined by means of vital staining
with Hoechst 33258 and flow cytometry after 24 h and/or 48 h
stimulation with the indicated substances. Results that represent
duplicates or several independent experiments are presented as
means6SD.
Found at: doi:10.1371/journal.ppat.1000554.s006 (0.16 MB PDF)
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